Join us on Thursday, April 29 at 3pm GMT / 11am EST for an exclusive 30-minute FirstWord Pharma PLUS subscriber event led by Executive Editor Simon King. Register here
He will present results from a new survey of 110 endocrinologists assessing positive head-to-head data evaluating Eli Lilly’s first-in-class GIP/GLP-1 receptor antagonist tirzepatide versus Novo Nordisk’s Ozempic and discuss the potential implications on future prescribing trends.
Last month we ran a shorter snap-poll to 62 endocrinologists with results suggesting that tirzepatide is likely to enjoy very quick adoption if approved by regulators – will feedback from our more extensive survey, which will contextualise endocrinologist perception of new data for tirzepatide against current treatment trends, provide further evidence of practice-changing potential
To read more Physician Views articles, click here.